Cancer Treatment

now browsing by category

 

Dr. Clay Siegall and Seattle Genetics Offer Hope To Cancer Patients

At the helm of the leading innovative, antibody-drug conjugates biotechnology firm in the nation, is Clay B. Siegall, Ph.D. Siegall co-founded Seattle Genetics in 1998. Aside from the title of President, he also holds the positions of Chairman of the Board and Chief Executive Officer.

 

The focus of Seattle Genetics is on cancer antibody treatments and therapies. The treatments and therapies, known as antibody-drug conjugates (ADCs). ADC’s captures a monoclonal antibody’s targeting mechanism and produces producing cancer destroying elements to cells afflicted with cancer. ADC’s target only cancer cells and avoid non-cancerous cells. This process dramatically lowers the toxicity from chemotherapy and possibly enhances anti-tumor development. Seattle Genetics innovative technology fulfills the need for life-threatening solutions.

 

CEO, President, and Chairman of the Board, Clay B. Siegall career trained him as a scientist. His curiosity with a cure for cancer leads him to form Seattle Genetics. Seattle Genetics dedication towards contemporary innovation, determined research, and pharmaceutical drug development makes it a leader in the cancer biotechnology sector.

 

Dr.Siegall spearheaded Seattle Genetic’s successful 2011 effort in obtaining the United States Food and Drug Administration’s approval of ADCETRIS® (brentuximab vedotin). He worked closely with the Takeda Pharmaceutical Company, overseeing a joint marketing agreement and distribution effort. The agreement makes ADCETRIS the leading brand worldwide for cancer treatments. So successful is the product, 60 governmental authorities around the world have approved its use. As a result of its success, Seattle Genetics is establishing a vast array of proprietary ADC cancer treatments.

 

Seattle Genetic’s success in research technology of ADC’s enabled it to sign numerous strategic production and marketing licenses with Pfizer, Genentech (Roche), GlaxoSmithKline and AbbVie. These collaborative agreements brought Seattle Genetics over $325 million. With over 20 ADC’s in development, Dr. Siegall’s efforts have increased the firm’s capital income, securing more than $1.2 billion in public offerings and private and public solicitations.

 

More information about Dr. Clay B. Siegall, Ph.D. and Seattle Genetics is available at their website, http://www.seattlegenetics.com/